Transforming India into a Global Biopharma Hub

1. At a Glance

• Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) is a Union Budget 2026–27 initiative with a ₹10,000 crore five-year outlay to scale India's biologics and biosimilars ecosystem [S1][S2].
• Target: capture 5% of the global biopharmaceutical market and position India as a leading global biopharma manufacturing hub [S1][S2].
• Builds on the earlier National Biopharma Mission (NBM) – Innovate in India (i3), 2017, co-funded with the World Bank, executed by BIRAC under DBT [S3][S4].
• Convergence point for GS-III (S&T, economy, health) — pharma is a flagship "Atmanirbhar Bharat" sector.

2. Why in the News

• Union Budget 2026–27 (presented Feb 2026) announced Biopharma SHAKTI with ₹10,000 crore outlay over 5 years [S1][S2].
• Finance Minister's speech tied the scheme to creating a biomanufacturing hub and the "next industrial revolution" theme reiterated by MoS S&T Dr. Jitendra Singh [S2].

3. Background & Evolution

• 2017 (May): National Biopharma Mission "Innovate in India (i3)" launched; co-funded by the World Bank; implemented by BIRAC under DBT [S3][S4].
• NBM's stated aim: make India a USD 100 billion biotech industry by 2025 and capture 5% of the global pharma share [S4].
• NBM scale (as of 2023): 101 projects, 150+ organisations, 30 MSMEs, 1,000+ jobs, 18+ products launched (vaccines, biotherapeutics, diagnostics, devices), 22 shared infra facilities, 16 clinical trial networks [S4].
• 2024–26: Production Linked Incentive (PLI) for Pharma and Bulk Drugs continuing; momentum to address dependence on imported biologics → culminates in Biopharma SHAKTI in Budget 2026–27 [S1].

4. Core Static Facts

Five scheme components (Biopharma SHAKTI): Biopharma Discovery Grant Fund & Discovery-Development Equity Fund; Biopharma-focused NIPER + National Biopharma R&D Network; India Clinical Trials Sites Network; Fermentation-based Bulk Drugs & Building Blocks Manufacturing Incentive; Biopharma Delivery Devices & Packaging Ecosystem [S2].

5. Multi-Dimensional Analysis

Economic - Targets capture of 5% of the global biopharma market — currently India holds a small biologics share despite leading in generics [S1]. - Reduces import dependence on bulk drugs/fermentation-based KSMs (echoing PLI Bulk Drug Parks logic) [S2]. - Equity Fund signals state-supported risk capital for biotech start-ups, addressing the deep-tech capital gap.

Scientific / Technological - Shift from small-molecule generics to complex biologics & biosimilars — monoclonal antibodies, recombinant proteins, cell & gene therapies [S1][S2]. - R&D network + NIPER expansion seeks to plug translational research gaps shown by NBM data (18 products from 101 projects) [S4].

Administrative / Governance - Strengthening CDSCO with a scientific review cadre to align approval timelines with US-FDA/EMA [S2]. - 1,000-site clinical trial network addresses fragmented, slow trial ecosystem — a known bottleneck.

Strategic / Geopolitical - India already styled the "Pharmacy of the World" (vaccine diplomacy, Vaccine Maitri). Biologics dominance is the next vector of pharma soft power. - Reduces strategic vulnerability in biosimilars where China has been scaling rapidly.

Social / Health - Indigenous biosimilars expected to lower costs of cancer, autoimmune and diabetes therapies — equity dimension for Ayushman Bharat coverage.

6. Recent Developments (12–18 months)

• Feb 2026: Budget 2026–27 announces Biopharma SHAKTI, ₹10,000 crore/5 yrs [S1][S2].
• Feb 2026: PIB Backgrounder "Transforming India into a Global Biopharma Hub" released as part of Budget 2026–27 series [S1].
• 2024: NBM "celebrating 5 years" review — consolidated outcomes published by DBT [S4].
• Continued PLI for Pharmaceuticals (₹15,000 cr) and PLI for Bulk Drugs/KSMs (₹6,940 cr) running in parallel.

7. Prelims Hooks

• Biopharma SHAKTI outlay: ₹10,000 crore over 5 years [S1].
• SHAKTI expands to Strategy for Healthcare Advancement through Knowledge, Technology and Innovation [S1].
• Global biopharma market-share target: 5% [S1].
• National Biopharma Mission launched: May 2017 [S3][S4].
• NBM tagline: "Innovate in India (i3)" [S4].
• NBM implementing agency: BIRAC (Biotechnology Industry Research Assistance Council) — a DBT PSU [S4].
• NBM co-funder: World Bank [S4].
• Budget 2026–27 announces network of 1,000 accredited clinical trial sites [S2].
• Scheme adds 3 new NIPERs and upgrades 7 existing ones for biopharma [S2].
• Regulator targeted for capacity upgrade: CDSCO (under Ministry of Health & Family Welfare) [S2].
• NBM by 2023: supported 101 projects, 30 MSMEs, 18+ marketed products [S4].
• DBT supported indigenous DNA vaccine: ZyCoV-D by Zydus Cadila — world's first plasmid DNA COVID-19 vaccine [S3].

8. Mains Relevance

• GS-III — Indian Economy (industrial policy, manufacturing); Science & Technology (indigenisation, biotech); Investment Models (PLI, equity funds).
• GS-II — Government schemes for health sector; role of regulators (CDSCO).
• Question stems: 1. "Examine how the Biopharma SHAKTI scheme builds on the National Biopharma Mission to reposition India from a generics powerhouse to a biologics hub." (GS-III) 2. "Discuss the regulatory and R&D bottlenecks that have prevented India from capturing a larger share of the global biopharmaceutical market." (GS-III) 3. "Public funding alone cannot create a biotech ecosystem — it must be matched by risk capital, regulatory reform and clinical trial capacity." Comment. (GS-III)

9. Related Topics to Study Next

• PLI for Pharma & Bulk Drugs / Bulk Drug Parks — complementary supply-side push.
• National Biotechnology Development Strategy (BioE3 policy, 2024) — DBT's biomanufacturing vision.
• CDSCO & New Drugs and Clinical Trials Rules, 2019 — regulator framework.
• TRIPS & compulsory licensing (Patents Act §84) — generics-vs-biologics IP debate.
• Ayushman Bharat PM-JAY — demand-side affordability link.
• Vaccine Maitri / WHO listing of Indian vaccine makers — global health diplomacy.
• BIRAC and Bio-incubators (BioNEST) — start-up ecosystem.
• Genome India Programme — adjacent biotech mission.

10. Common Errors / Trap Areas

• SHAKTI ≠ generic pharma scheme. It is biologics/biosimilars-focused, distinct from PLI for Pharma.
• NBM is under DBT/BIRAC, not Department of Pharmaceuticals — students often mix the two ministries.
• NBM was launched 2017, not at COVID time; ZyCoV-D came later under separate DBT support.
• CDSCO sits under MoHFW, not under Department of Pharma — common error.
• "5% global share" target dates back to the 2017 NBM vision and is reiterated by Biopharma SHAKTI — it is not a new 2026 number [S4][S1].
• NIPER network is under Department of Pharmaceuticals, not DBT.

11. Sources

• [S1] Transforming India into a Global Biopharma Hub – Budget 2026-27 Series, PIB Backgrounder — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2222079 — (tier 1)
• [S2] Biopharma SHAKTI proposed in Union Budget 2026-27, PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221443 — (tier 1)
• [S3] National Biopharma Mission, PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1606249 — (tier 1)
• [S4] National Biopharma Mission supporting 101 projects (Dr Jitendra Singh) / NBM 5-year review, PIB — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=1941006 ; https://www.pib.gov.in/PressReleasePage.aspx?PRID=2043311 — (tier 1)